KRAS and colorectal carcinoma: In agreement, treatment with anti‐CD3 resulted in massive apoptosis in tumor‐specific CTLs from KRAS mutant, but not wild type, CRC (Figure 4I,K), indicating that tumor‐specific CTLs in KRAS mutant CRC had increased sensitivity to AICD.